Immune Activation and Cellular Response From Enzalutamide Alone or With Radium223 in Men With Metastatic, Castration-Resistant Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Enzalutamide (Primary) ; Radium 223 chloride (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Dec 2018 Planned End Date changed from 26 Nov 2023 to 21 Nov 2023.
- 10 Dec 2018 Planned primary completion date changed from 26 Nov 2022 to 21 Nov 2022.
- 10 Dec 2018 Status changed from not yet recruiting to recruiting.